Back to all studies
RecruitingACTRN12620000703909

Candesartan for depression in bipolarity

This study is recruiting in Australia. It is testing candesartan for depression in bipolarity.

BipolarityDrugOver 18 Years
Need help deciding?

Ask HopeStage to review this study with me

Leave your email and HopeStage can help you better understand this study.

Loading the security check...
Study reference: ACTRN12620000703909. HopeStage can help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

This Australian study is testing whether candesartan, used as an add-on to usual treatment, can help reduce depressive symptoms for adults experiencing depression in bipolarity. Participants are assigned to candesartan or placebo and followed over 16 weeks. HopeStage lists this study for discovery only; eligibility and participation details must be confirmed by the official study team.

What to expect

Your next step

The registry lists recruiting status in Australia, with sites in Queensland and Victoria. The study involves a medication or placebo, follow-up assessments, and safety checks. Before considering participation, check the official ANZCTR record, ask about visit timing and monitoring, and discuss the study with your healthcare professional.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Sponsor
Deakin University
Sponsor type
University
Main activity
medication or study treatment
Intervention
Candesartan, Placebo
Time commitment
multiple visits or assessments
Study phase
Phase 2 / Phase 3
Enrollment
240
Recruitment status
Recruiting
Source
Official registry link
Public study data

Key study information

Official title
The Candesartan Adjunctive Bipolar Depression Trial - CADET: A double-blind, randomised, placebo-controlled trial to evaluate the effect of Candesartan on mood in patients with bipolar depression
Condition
Bipolar depression; Mental Health; Depression
Study status
Recruiting
Phase
Phase 2 / Phase 3
Sponsor / lead affiliation
Deakin University
Intervention
Candesartan, Placebo
Location / country
Australia
Contact
Michael Berk
Phone
+61 3 4215 3330
Registry
Australian New Zealand Clinical Trials Registry
External trial ID
ACTRN12620000703909
Last verified date
May 11, 2026
Why this study may matter

Why this study may matter

This study may matter because it is evaluating Candesartan, Placebo in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular follow-up, often through questionnaires or interviews.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Official title
The Candesartan Adjunctive Bipolar Depression Trial - CADET: A double-blind, randomised, placebo-controlled trial to evaluate the effect of Candesartan on mood in patients with bipolar depression
Source
Australian New Zealand Clinical Trials Registry
Official registry link
Open official registry
External trial ID
ACTRN12620000703909
Last verified date
May 11, 2026
Open source record
Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is Candesartan for depression in bipolarity?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Deakin University. Based on the sponsor name or official registry information, it appears to be a university. Collaborators include University of Melbourne, University of Sydney, Barwon Health, Eastern Health, The Melbourne Clinic, Albert Road Clinic, Royal North Shore Hospital, Toowong Specialist Clinic. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is Phase 2 / Phase 3. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. The planned or actual enrollment is 240 participants. Larger studies may provide more information about how the intervention performs across a wider group, but size alone does not prove that a study is right for you. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Candesartan Trial for Depression in Bipolarity in Australia | HopeStage Research